What are the side effects and hazards of gaffetomab?

Glofitumab (Glofitamab) is an innovative bispecific T cell engaging antibody that exerts anti-tumor effects by activating T cells to launch immune attacks on B cells. However, precisely because this mechanism of activating T cells is powerful and rapid, it also means that patients may face a series of immune-related side effects during treatment, especially more serious complications such as cytokine release syndrome (CRS). The side effects of Glofitamab are typical of immunotherapy drugs. Some patients may experience significant discomfort in the early stages of treatment, which may even be life-threatening, and a high degree of vigilance is required.

The most concerning side effect is cytokine release syndrome (CRS). This reaction is caused by T cells being activated on a large scale after binding to tumor cells and releasing a large amount of inflammatory factors. CRS presents with symptoms such as fever, chills, hypotension, dyspnea, myalgia, and fatigue. In severe cases, shock or organ dysfunction may even occur. In order to reduce the incidence of CRS, a stepwise dose escalation strategy is usually adopted in clinical use, and leading monoclonal antibody treatment is given before the use of gaffetuzumab to "remove" part of the tumor load, thereby reducing the intensity of initial T cell activation.

Nervous system toxicity (ICANS, immune effector cell-associated neurotoxicity) is another type of adverse reaction worth noting. Although the incidence rate is relatively low compared to CAR-T therapy, some patients may still experience speech impairment, confusion, seizures, or behavioral changes after treatment. Such reactions are more common after the occurrence of severe CRS and require timely intervention.

In addition, gaffetuzumab may also cause immune-mediated autologous tissue damage, such as rash, elevated liver enzymes, thyroid dysfunction and other rare but important adverse reactions. The risk of infection also increases under immunosuppression, especially respiratory and urinary system infections. Some patients may experience symptoms such as fever, cough, and frequent urination. Clinical evaluation needs to be combined with blood and inflammatory indicators.

Reference materials:https://www.drugs.com/glofitamab.html